Education and Resources
Podcast Episode 14: Becoming InFORMed
Before taking part in a medical or health study, participants need to give their informed consent in a Participant Information and Consent Form (PICF). The purpose of the PICF is to provide information about what the study involves so potential participants can decide if it is right for them. Over the years PICFs have become […]
Read More
2026 Podcast Season: More About NAMs
When a potential new medicine is tested on humans for the first time it is a milestone. It is thoroughly tested for safety before reaching this stage. Often, it’s tested on animals, but increasingly New Approach Methodologies (NAMs) are being used (previously known as Non-Animal Models). NAMs are non-animal or reduced-animal scientific methods used to […]
Read More
National Statement Updates 2025
The National Statement on Ethical Conduct in Human Research is the principal reference for research involving humans in Australia and is the guiding document for Human Research Ethics Committees. The National Statement is released by the National Health and Medical Research Council (NHMRC) and is periodically updated to stay relevant to evolving research practices, ethical […]
Read More
Podcast Episode 11: From Lab To Life
In 2004 Bellberry was founded as a paradigm breaker. We are an institutionally independent not-for-profit company that offers Human Research Ethics Committee services. Today Bellberry provides ethics reviews for more than 40% of the CTN clinical trials taking place in Australia and has re-invested $12 million into the research sector. In 2024 we celebrated 20 […]
Read More
Latest Podcast Episode – From Lab To Life
Without the patient or participant we would not have clinical trials. These are the people who, in some cases, are volunteering to have treatments that have never been tried on humans before. In It’s All About the Participant we hear first-hand about what it’s like to be the participant and ask how could the experience […]
Read More
Clinical Trial Activity Report for 2023
International investment strong in Australian early phase trials Overseas companies invest in two-thirds of all Australian clinical trials reviewed by Australia’s largest reviewer of human research, Bellberry, according to its Clinical Trial Activity Report (CTAR). Bellberry reviews more than 40% of CTN (Clinical Trial Notification) trials in Australia and each year releases its CTAR on […]
Read More
Latest Podcast Episode – From Lab To Life
In this episode of From Lab to Life, we hear the insights from some of the smartest researchers in the country about how they have succeeded in their careers. In ‘Speaking From Experience’ we hear from Laureate Professor Ingrid Scheffer, Professor Doug Hilton, Emeritus Professor Ian Frazer, Professors Marnie Blewitt, Kim Jacobson and Di Yu […]
Read More
New Podcast Episode – From Lab To Life
Bellberry’s award winning work is supported by a dedicated, talented and growing team. In this episode of From Lab to Life, we meet some of the members of the Bellberry team and find out why they do what they do. They give us an insight into the organisation, the work they do and what gets […]
Read More
Bellberry Clinical Trial Activity Report for 2022
On International Clinical Trials Day, we’re proud to publish the Bellberry Clinical Trial Activity Report for 2022. This annual publication represents over one third of the Australia wide CTN trial activity across the development lifecycle. This report demonstrates capability and capacity in a broad range of research areas. It also captures the originating funding location […]
Read More
Quality update: progress and final reporting refresher
Progress reporting realignment initiative During 2021 Bellberry implemented a new approach to annual reporting, making use of technology solutions to improve performance. The primary objectives of the project were to: Support researchers maintain compliance with the terms and conditions of ethical approval and obligations under the National Statement on Ethical Conduct in Human Research. Move […]
Read More
Bellberry Quality Update: HREC membership lists
As per the National Statement on Ethical Conduct in Human Research (2007) Updated 2018, at the end of each HREC meeting, Bellberry Administration creates a ‘Member List’ as per the example below: The member composition at the meeting may change from protocol to protocol, in consideration of the expertise required and conflicts of interest. The […]
Read More
Safety reporting requirements update
As most of our users have now formalised local governance processes for internal safety reporting, we have updated MAR G2 Safety reporting, to no longer require the submission of SUSARs for individual events at Bellberry sites. To assist sites in understanding the updated requirements, if Bellberry’s administrative team receives documentation not outlined in MAR […]
Read More
Progress and Final Reporting Refresher
Progress reporting realignment initiative We have seen significant improvement with compliance since Bellberry began a significant progress reporting realignment initiative. The primary objectives of the project were to: Progress and final reporting: guidance materials Bellberry provides the following documents relating to progress and final reporting: MAR G4 Progress and final reports This guidance outlines researcher […]
Read More
Radiation Refresher
Bellberry provides the following documents relating to applications that involve radiation: BA G13 Ionising RadiationThis guidance outlines the requirements where research applications involve the use of ionising radiation. BA F13.1.1 Standard clauses – ionising radiationThis form provides sites with example clauses for inclusion in the PICF.If the medical imaging used is the same as standard […]
Read More
Bellberry Clinical Trial Activity Report 2020
Bellberry is the largest independent reviewer of CTN trials in Australia. This year on Clinical Trials Day, we’re pleased to share a summary report which describes research activity overseen by Bellberry HRECs through 2020. This activity report represents a significant proportion of the Australia wide CTN trial activity across the development lifecycle. It demonstrates […]
Read More